[123I]CC1: A PARP-Targeting, Auger Electron-Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer

Conclusion: Taken together, these results show the potential of [123I]CC1 as a radioligand therapy for PARP-expressing cancers.

Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Chan, C. Y., Chen, Z., Guibbal, F., Dias, G., Destro, G., ONeill, E., Veal, M., Lau, D., Mosley, M., Wilson, T. C., Gouverneur, V., Cornelissen, B. Tags: Basic Science Investigations Source Type: research